• 1
    Steffen R, Behrens H. Traveller's malaria. Parasitol Today 1992; 8 (2):6166.
  • 2
    Jelinek T, Loscher T, Nothdurft HD. High prevalence of antibodies against circumsporozoite antigen of Plasmodium falciparum without development of symptomatic malaria in travelers returning from sub-Saharan Africa. J Infect Dis 1996; 174 (6):13761379.
  • 3
    Schlagenhauf P, Steffen R, Tschopp A, et al. Behavioral aspects of travelers in their use of malaria presumptive treatment. Bull World Health Organ 1995; 73 (2):215221.
  • 4
    Palmer KJ, Holliday SM, Brogden RN. Mefloquine, a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45 (3):430475.
  • 5
    Crevoisier C, Handschin J, Barré J, et al. Food increases the bioavailability of mefloquine. Eur J Clin Pharmacol 1997; 53:135139.
  • 6
    Pennie RA, Koren G, Crevoisier C. Steady state pharmacokinetics of mefloquine in long-term travellers. Trans R Soc Trop Med Hyg 1993; 87:459462.
  • 7
    Gimenez F, Pennie RA, Koren G, Crevoisier C, et al. Stereoselective Pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. J Pharm Sci 1994; 83: 6: 824827.
  • 8
    Crevoisier C, Joseph I, Fischer M, Graf H. Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study. Antimicrob Agents Chemother 1995; 18921895.
  • 9
    Weidekamm E, Rüsing G, Caplain H, Sörgel F, et al. Lack of bioequivalence of a generic mefloquine tablet with the standard product. Eur J Clin Pharmacol 1998; 54:615619.
  • 10
    Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasit 1993; 44:257265.
  • 11
    Schlagenhauf P, Lobel HO, Steffen R, et al. Tolerability of mefloquine in Swissair trainee pilots. Am J Trop Med Hyg 1997; 56:235240.
  • 12
    Vuurman EFPM, Muntjewerff ND, Uiterwijk MMC, et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 1996; 50:475482.
  • 13
    MacPherson D, Gamble K, Tessier D, et al. Mefloquine tolerance-randomised, double-blinded, placebo-controlled study using a loading dose of mefloquine in pre-exposed travellers. In: Program and Abstracts of the Fifth International Conference on Travel Medicine; March 24–27, 1997: Geneva, Switzerland. Abstract 220.
  • 14
    Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341:12991303.
  • 15
    Lobel HO, Miani M, Eng T, et al. Long term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341:848851.
  • 16
    Ohrt C, Richie TL, Widjaja H, et al. A double-blind, placebo-controlled trial of mefloquine versus doxycycline for the prophylaxis of malaria in Indonesian soldiers. Ann Intern Med 1997; 126:963972.
  • 17
    Rieckmann KH, Yeo AE, Davis DR, et al. Recent military experience with malaria chemoprophylaxis. Med J Aust 1993; 158:446449.
  • 18
    Pergallo MS, Sabatinelli G, Majori G, et al. Prevention and morbidity in non-immune subjects; a case-control study among Italian troops in Somalia and Mozambique, 1992–1994. Trans R Soc Trop Med Hyg 1997; 91:343346.
  • 19
    Axmann A, Félegyhazi CS, Huszar A, Juhasz P. Long term malaria prophylaxis with Lariam in Cambodia, 1993. Travel Med Int 1994; 12: 1: 1318.
  • 20
    Hopperus Buma APCC, van Thiel PPAM, Lobel HO, et al. Long term malaria chemoprophylaxis with mefloquine in Dutch Marines in Cambodia. J Infect Dis 1996; 173:15061509.
  • 21
    Sanchez JL, DeFraites RF, Sharp TW, Hanson RK. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet 1993; 341:10211022.
  • 22
    Wallace MR, Sharp TW, Smoak B, et al. Malaria among United States troops in Somalia. Am J Med 1996; 100:4955.
  • 23
    Bwire R, Slootman EJH, Verhave JP, et al. Malaria anticircumsporozoite antibodies in Dutch soldiers returning from sub-Saharan Africa. Trop Med Int Health 1998; 3: 1: 6669.
  • 24
    Muehlberger N, Jelinek T, Schlipkoeter U, et al. Effectiveness of chemoprophylaxis and other determinants of malaria in travellers to Kenya. Trop Med Int Health 1998; 3(5)357363.
  • 25
    Lobel HO, Varma JK, Miani N, et al. Monitoring for mefloquine-resistant Plasmodium falciparum in Africa: implications for travelers health. Am J Trop Med Hyg 1998; 59:129132.
  • 26
    Magill AJ, Smoak BL. Failure of mefloquine chemoprophylaxis for malaria in Somalia. Letter. N Eng J Med 1993; 329: 16: 1206.
  • 27
    Wallace MR, Sharp TW, Romajzl PJ, Magill HO. Malaria among US troops in Somalia. Clin Infect Dis 1994; (3) 580, Abstr 101.
  • 28
    Nozais JP. Un nouveau cas probable de resistance croisee de Plasmodium falciparum viv-a-vis de la mefloquine et de l'halofantrine, en provenance de Sierre Leone. Medecine et Maladies Infectieuses 1992; (22) No. 3, 421423.
  • 29
    Delmont J, Faugere B, Doury JC, Bourgeade A. Paludisme a Plasmodium falciparum consectif a un echec de prophylaxie par mefloquine lors d'un sejour en Cote d'Ivoire. Medecine et Maladies Infectieuses. 1992; (22) No. 3, 418420.
  • 30
    Matteelli A, Chiodera A, Castelli F, et al. Failure of mefloquine chemoprophylaxis for malaria in Mozambique. J Travel Med 1995; 2:260261.
  • 31
    Kurds JD, Koros JK, Duffy PE, Green MD. Malaria prevention for travellers. (Letter; comment) JAMA 1998; 278 (21): 17671771.
  • 32
    Todd GD, Hopperus Buma AP, Green MD, et al. Comparasison of whole blood and serum levels of mefloquine and its carboxylic acid metabolite. Am J Trop Med Hyg 1997; 57 (4):399402.
  • 33
    Day JH, Behrens RH. Delay in onset of malaria with mefloquine prophylaxis. Lancet 1995; 345:398.
  • 34
    Mockenhaupt FP. Mefloquine resistance in Plasmodium falciparum. Parasitol Today 1995; 11 (7) 248253.
  • 35
    Amor D, Richards M. Mefloquine resistant P. vivax malaria in PNG. Med J Aust 1992; 156 (12) 883.
  • 36
    Chia JK, Nakata MM, Co S. Smear-negative cerebral malaria due to mefloquine-resistant Plasmodium falàpamm acquired in the Amazon. J Infect Dis 1992; 165 (3):599600.
  • 37
    Le Bras J, Durand R, Di Piazza JP, Pradines B, et al. Plasmodium falciparum resistance to mefloquine, chloroquine and cycloguanil and prevention of malaria in travelers from France to Africa. Presse Med 1998; 27 (28): 14191423.
  • 38
    Brasseur P, Kouamouo J, Moyou-Somo R, Druilhe P. Multidrug resistant falciparum malaria in Cameroon in 1987–1988. II Mefloquine resistance confirmed in vivo and in vitro and its correlation with quinine resistance. Am J Trop Med Hyg 1992; 46:814.
  • 39
    Behrens RH, Bradley DJ, Snow RW, Marsh K. Impact of UK malaria prophylaxis policy on imported malaria. Lancet 1996; (9023):344345.
  • 40
    Muentener P, Schlagenhauf P, Sceflfen R. Imported malaria in industrialized countries. Trends and perspectives. Bull World Health Organ; in press.
  • 41
    Peters W. Drug resistance in malaria parasites of animals and man. Adv Parasitol 1998; 41:158.
  • 42
    White NJ. Why is it that antimalarial drug treatments do not always work Ann Trop Med Parasitol 1998; 92 (4) 449458.
  • 43
    Peel SA, Bright P, Yount B, et al. A strong assocation between mefloquine and halofantrine resistance and amplification, overexpression and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am J Trop Med Hyg 1994; 51:648658.
  • 44
    Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdrl gene and cross resistance to halofantrine and quinine. Proc Nat Acad Sci USA 1994; 91:11431147.
  • 45
    Oduola AMJ, Omitowoju GO, Gerena L, Kyle DE, et al. Reversal of mefloquine resistance with penfluridol in isolates of Plasmodium falciparum from south-west Nigeria. Trans R Soc Trop Med Hyg 1993; 87:8183.
  • 46
    Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with the use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996; 313:525528.
  • 47
    Croft AMJ Toxicity of mefloquine is similar to that of other chemoprophylaxis. BMJ 1995; 3: 11: 191.
  • 48
    Phillips MA, Kass RB. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med 1996; 3:4045.
  • 49
    Jaspers CA, Hopperus Buma AP, van Thiel PP, van Hulst RA, et al. Tolerance of mefloquine prophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996; 55 (2):230234.
  • 50
    Schlagenhauf P, Steffen R, Lobel H. Johnson R, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996; 1(4): 485494.
  • 51
    CIOM International reporting of adverse drug reactions. CIOMS Working Group Report Geneva : World Health Organization, 1987.
  • 52
    Croft AJM, World MJ. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet 1996; 347:326.
  • 53
    Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. Br Med J 1997; 315:14121416.
  • 54
    Behrens RH, Erny S, Maradit H, Houston S, et al. Mefloquine to prevent malaria. (Multiple letters) Br Med J 1998; 316:19801981.
  • 55
    Bern JL, Kerr L, Stürchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95:167179.
  • 56
    Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Safety 1995; 12:370383.
  • 57
    Wittes RC, Sagmur R. Adverse reactions to mefloquine associated with ethanol ingestion. Can Med Assoc J 1995; 152:515517.
  • 58
    Mittelholzer ML, Wall M, Steffen R, Stürchler D. Malaria prophylaxis in different age groups. J Travel Med 1996; 4:219223.
  • 59
    Jerling M, Rombo L, Hellgren U, Bergqvist Y, et al. Evaluation of mefloquine adverse effects in relation to the plasma concentration. Fourth International Conference on Travel Medicine. Acapulco, Mexico, April 23–27, 1995. Abstract No. 95.
  • 60
    Hennequin C, Bouree P, Bazin N, et al. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Interna Med 1994; 20:23602362.
  • 61
    Clattenburg RN, Donnelly CL. Case study:neuro-psychaitric symptoms associated with the antimalarial agent mefloquine. J Am Acad Child Adolesc Psychiatry. 1997; 36(11): 16061608.
  • 62
    Lench P, Bradley D, Warhurst D. Psychological problems after mefloquine and chloroquine. BMJ. 1995: 311: 192.
  • 63
    Carme B, Nevez G, Peguet C, Bouko I. Intolerance neuropsychique au sours de la chimiprophylaxis antipalustre par la mefloquine. A propos de 5 observations. Bull Epi Herbdomadaire 1994; 34: 155.
  • 64
    Meszaros K. Acute psychosis casused by mefloquine prophylaxis Can J Psych 1996; 41:196.
  • 65
    Hollweg M, Soyka M, Greil W. Mefloquininduzierte Psychosen—Probleme der Kausalzuordnung anhand zweier kasuistischer Berichte. Psychiatrische Praxis 1995; 22:(1) 3336.
  • 66
    Piening RB, Young SA. Mefloquine induced psychosis. Ann Emergency Med 1996; 27:(6) 792.
  • 67
    Grupp D, Rauber A, Froescher W. Neuropsychiatrische Stoerungen nach Malariaprophylaxe mit Mefloquin. Aktuelle Neurologie 1994; 21(4) 134136.
  • 68
    Marsepoil T, Petithory J, Faucher JM, Ho P, et al. Encephalopathie et troubles amnesiques au cours des traitments par la mefloquine. Revue de Medecine Interne 1993; 14(8)788791.
  • 69
    Recasens C, Zittoun C, Feline A. Un episode psychotique au retour dùn voyage en Afrique: implication possible de la mefloquine. Annales de Psychiatrie 8: (2) 100103.
  • 70
    Folkerts H, Kuhs H. Psychotische Episode infolge Malariaprophylaxe mit Mefloquine. Eine kasuistische Mitteilung. Der Nervenarzt. 1992: 63(5) 300302.
  • 71
    Caillon E, Schmitt L, Moron P. Acute depressive symptoms after mefloquine treatment. Am J Psychiatry 1992: 149(5) 712.
  • 72
    Ruff TA, Sherwen SJ, Donnan GA. Seizure associated with mefloquine for malaria prophylaxis. Med J Aust 1994; 161:453.
  • 73
    Pous E, Gascon J, Obach J, Corachan M. Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject. Trans R Soc Trop Med Hyg 1995; 89:434.
  • 74
    Adamolekun B. Epileptogenic potential of antimalarial drugs. West Afr J Med 1993; 12(4) 231232.
  • 75
    Ries S. Zerebrale Krampfanfalle während einer Malariaprophylaxe mit Mefloquin. Deutsche Medizinische Wochenschrift 1993; 118:19111912.
  • 76
    Olsen PE, Kennedy CA, Morte PD. Paresthesias and mefloquine prophylaxis. Ann Intern Med 1992; 117(12) 10581059.
  • 77
    White AC, Runnels JH. Cutaneous vasculitis associated with mefloquine. Ann Intern Med 1995; 123 (11) 894.
  • 78
    Martin GJ, Malone JL, Ross EV Exfoliative dermatitis during malaria prophylaxis with mefloquine. CID 1993; 16(2) 341342.
  • 79
    MacBride SR, Lawrence CM, Pape SA, Reid CA. Fatal toxic epidermal necrolysis associated with mefloquine prophylaxis. Lancet 1997; 349:101.
  • 80
    Nicolas X, Touze JE. La toxicite cardiaque des antipaludiques. Medecine Tropicale 1994; 54(4) 361365.
  • 81
    Richter J, Burbach G, Hellgren U, et al. Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine. Lancet 1997; 349:101102.
  • 82
    Fonteyne W, Bauwens A, Jordaens L. Atrial flutter with 1:1 conduction after administration of the antmalarial drug mefloquine. Clin Cardiol 1996; 19 (12) 967968.
  • 83
    Stracher AR, Stoeckle MY, Giordano MF. Aplasric anemia during malaria prophylaxis with mefloquine. CID 1994; 18 (2) 263264.
  • 84
    Phillips M. Antimalarial mefloquine. Med J Aust 1994; 161:227228.
  • 85
    Drent M. Drug induced pneumonia associated with hemizygote glucose-6-phosphate-dehydrogenase deficiency. Eur J Haematol 1998; 61 (3) 218220.
  • 86
    Davis TME, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo controlled trial. Br J Clin Pharmacol 1996; 42:415421.
  • 87
    Hessen-Soederman AC, Bergenius J, Berggren I, Bergqvist Y, et al. Mefloquine prophylaxis, and hearing, postural control and vestibular functions. J Travel Med 1995; 2(2) 6669.
  • 88
    Handschin JC, Wall M, Steffen R, Starchier D. Tolerability and effectiveness of malaria chemoprophylaxis with mefloquine or chloroquine with or without co-medication. J Travel Med 1997; 4(3)121127.
  • 89
    News Lancet 1998; 352: 1447.
  • 90
    Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double blind, placebo controlled study. J Infect Dis 1994; 169:595603.
  • 91
    Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55:5056.
  • 92
    Steketee RW, Wirima JJ, Hightower AW. Slutsker L, et al The effect of malaria and malaria prevention on offspring birth-weigth, prematurity and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg 1996; 55(1 Suppl)3341.
  • 93
    Vanhauwere B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg 1998; 58(1)1721.
  • 94
    Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Safety 1996; 14:131145.
  • 95
    Balocco R. Bonati M. Mefloquine prophylaxis against malaria for female travellers of childbearing age. Lancet 1992; 340:309310.
  • 96
    Smoak BL, Writer JV, Keep LW, et al. The effects of inadvertant exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army service women. J Infect Dis 1997; 176:831833.